Briacell Therapeutics Corp BCTX

$3.56 +0.06 (1.71%)

Valuation

Market cap
29,884,000
Revenue TTM
$0
Net income TTM
$-26,310,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
49,800
Avg volume
311,990
Day's range
$3.45 – $3.64
Shares out
8,700,000
Stochastic %K
41%
Beta
1.21
Analysts
Strong Buy
Price target
$40.00

Price

Company profile

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator...

Show more

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate the clinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
604 921 1810
Website
https://briacell.com
Address
Bellevue Centre, Suite 300 235 -15th Street, West Vancouver, Canada

Latest news

Stocktwits

Biotechlineup Oct 28, 4:05 AM
$NVAX $BCTX $SMMT $MRNAMODERNA’s cancer vaccine “ has not met expectations “ . BriaCell utilizes OFf shelf cellular matching, Novavax will utilize Matrix M in Off shelf cancer vaccines Old adjuvants only trigger antibodies, Matrix M induces robust MHC-I and MHC-II cross-presentation. This means it can take pre manufactured tumor protein fragments (Off shelf tumor antigens) and train killer CD8+ T-cells to hunt down a tumor instantly upon injection, completely bypassing the need to sequence individual patient biopsies. Summits ivonescimab with a PDF1/ anti vegf mechanism is the future bispecific, cancer vaccines formulated with Matrix M are designed to act as the ideal combination partner. Matrix M driven vaccines can generate a broad army of tumor specific T-cells, while a bispecific antibody like ivonescimab clears the vascular and PD-1 roadblocks to let those T-cells flood into the tumor tissue. Matrix M serves as an essential tool for high-valency and rapid-response immunology.
0 replies
SmallCapVoice Oct 27, 6:27 PM
Featured in The American Journal of Managed Care: BriaCell’s investigational Bria-IMT is in Phase 3 testing for metastatic breast cancer after ADC treatment. Phase 2 data showed median overall survival of 16.6 months. Read the feature here: https://briacell.com/media-coverage/ $BCTX
0 replies
JediGreen Oct 27, 5:09 PM
$BCTX https://youtu.be/5degIsw-fTI
0 replies
prismmarketview Oct 27, 4:28 PM
For the first time, a personalized cancer vaccine has succeeded in a Phase 3 trial. Merck $MRK and Moderna $MRNA ’s vaccine cut the risk of melanoma recurrence or death by 42% alongside Keytruda. It’s made from each patient’s own tumor, which takes weeks. These small caps are developing off-the-shelf approaches: $ANIX : a breast cancer vaccine with Cleveland Clinic, preparing for Phase 2 $BCTX : an off-the-shelf cell-based immunotherapy in a pivotal Phase 3 for metastatic breast cancer $CADL : a prostate cancer immunotherapy with positive Phase 3 data, with a BLA planned for Q4 https://prismmarketview.com/merck-and-modernas-cancer-vaccine-breakthrough-puts-off-the-shelf-immunotherapy-small-caps-in-focus/
0 replies
smallpower17 Oct 27, 2:50 PM
$BCTX "I’ve been in the trial a couple of months. No side effects and cancer markers are down which is awesome. This is my 8th line of treatment in 7 years and the first time markers are down!" "I am and getting good results!" From Facebook: these quotes are reportedly from a patient (same patient made both of these comments) in BriaCell's Phase 3 trial.
1 replies
CoffeeRocks Oct 27, 1:09 PM
$VKTX $LPCN $HIMS $BCTX $ABCL One to watch 👀 Earnings ++
0 replies
Xyz_83 Oct 26, 7:06 PM
$BCTX found this on Reddit and made some DD, this looks promissing!! With this Biotech winter i hear some whisper in the wind saying 'buy, buy, buy"
2 replies
CoffeeRocks Oct 26, 4:12 PM
$ZENA $BCTX $XNDU $ABCL $CGC Canadian companies getting a good spanking by US peers
0 replies